Corporate News
Bayer HealthCare Completes Acquisition of Western OTC Cough and Cold Business of Topsun Science and Technology
Significantly Strengthens Consumer Care Division’s Business in High Growth Chinese OTC Market more
Bayer HealthCare acquires hematology development portfolio featuring MAXY-VII from Maxygen
Phase 1 clinical testing expected to commence in third quarter of 2008 / Transaction includes license to Maxygen’s novel biotechnology research platform more
Bayer concludes supply and licensing agreements for Yasmin® and YAZ® with Barr for the United States
Appeal of court decision invalidating Yasmin patent will continue / Further growth of Bayer’s Women’s Healthcare Business Unit expected more
Bayer receives Environmental Award from the Federation of German Industries
Energy-efficient process recycles chlorine from hydrochloric acid / Industrial application in Germany and China / Bayer Management Board member Dr. Plischke: “Increase in energy efficiency brings... more
Bayer plans to invest EUR 100 million in Brazil
Wenning: “Brazil is our biggest market in Latin America” more
Bayer CEO Werner Wenning receives prestigious McCloy Award
Former German Foreign Minister Hans-Dietrich Genscher presents the honor in New York more
Bayer will use tobacco plants to produce medicines
First development candidate from the new plant for cancer indication non-Hodgkin’s lymphoma – Clinical phase I could start in 2009 / Bayer has invested over EUR 10 million in Halle since 2006 more
Bayer Climate Program makes great advances
Climate protection projects rigorously implemented / Commitment to global health care provision / EUR 45 million spent annually to support 300 social projects worldwide / EUR 500,000 per year alone... more
Bayer HealthCare successfully completes acquisition of Sagmel, Inc.’s OTC Business
Bayer Consumer Care’s Presence in Eastern Europe Significantly Strengthened more
Bayer increases aid to disaster victims in China and Burma
Cash and material donations now stand at more than EUR 1.4 million more
Rivaroxaban One Tablet/Once-Daily Superior to Twice-Daily Injectable Enoxaparin in Preventing Venous Blood Clots after Total Knee Replacement Surgery in Pivotal Phase III Trial
Rivaroxaban is First Oral Anticoagulant to Achieve Superior Efficacy over the Twice-Daily Injection of Enoxaparin while Maintaining Low Major Bleeding Rates / RECORD4 Confirms Results of RECORD1, 2... more
Nexavar Significantly Extends Overall Survival in Liver Cancer
Trial Results Confirm Efficacy for Population Most Affected by the Disease more
Bayer to Help Victims of Natural Disasters in China and Burma
Goods and Funds Donation in the Amount of 350,000 Euros more
Bayer lays the foundation for its zero-emission building in India
The “EcoCommercial Building” concept saves 70 percent of electrical energy / Chairman of the Bayer Board of Management Werner Wenning: “A milestone in the Bayer Climate Program” / More buildings to... more
Bayer and Regeneron start additional Phase 3 Study for VEGF Trap-Eye in Wet Age-related Macular Degeneration
International study to evaluate efficacy and safety in treating a leading cause of blindness more
Bayer Schering Pharma to market new low-dose oral contraceptive YAZ® in Europe
Berlin, May 6, 2008 – Bayer Schering Pharma’s new low-dose oral contraceptive YAZ® has been approved in the EU.YAZ® will be the first oral contraceptive on the European market containing the unique... more
“2007 was Bayer’s most successful year to date”
Previous year’s record levels and earnings targets exceeded / Dividend to be raised 35 percent to EUR 1.35 / Good start to fiscal 2008 / Bayer Climate Program being implemented and expanded more
Bayer off to an excellent start in 2008
Sales up 2.4 percent to EUR 8,536 million / EBITDA before special items up 9.8 percent to EUR 2,185 million / EBIT before special items up 8.9 percent to EUR 1,497 million / Full-year guidance for... more
Bayer Challenges Watson and Sandoz U.S. ANDA Filings on Yasmin®
Leverkusen, April 21, 2008 – Bayer confirmed that Bayer Schering Pharma AG and Bayer HealthCare Pharmaceuticals Inc. filed a patent infringement lawsuit in U.S. Federal Court in the Southern District... more
Bayer donates €250,000 for patients with hemophilia and provides nearly 1 million international units of Kogenate®
World Hemophilia Day on April 17th more
Bayer HealthCare Affiliate MEDRAD Announces Completion of Subsequent Offering Period for Shares of Possis Medical
Merger to Be Completed Shortly more
Bayer appeals invalidity ruling on its Yasmin® Patent
Appeal will be heard by the Federal Circuit more
Bayer HealthCare Affiliate MEDRAD and Possis Medical Sign Definitive Merger Agreement
Leverkusen, Germany, / Minneapolis, MN, USA – Bayer HealthCare affiliate MEDRAD, Inc., Warrendale, PA and Possis Medical, Inc., Minneapolis, MN, (Nasdaq: POSS), announced today that they have entered... more
Nexavar® Approved for the Treatment of Kidney Cancer in Japan
First approved oral targeted therapy for metastatic RCC in Japan more
Bayer extends product portfolio for liver cancer patients in Japan
Japanese authorities grant priority review status for Nexavar® in liver cancer / Launch of liver-specific contrast agent Primovist® in Japan more
Bayer establishes US special access program for Leukine® while replacing current liquid formulation
Leukine lyophilized formulation temporarily reserved for patients with Acute Myelogenous Leukemia (AML) and those experiencing bone marrow transplantation graft failure or engraftment delay / Bayer... more
US Food and Drug Administration Approves RECOTHROM™
Leverkusen – Bayer HealthCare announced today that its partner, ZymoGenetics Inc., received US Food and Drug Administration (FDA) approval of RECOTHROM™ Thrombin, topical (recombinant) for use as a... more
Archer Daniels Midland Company, Bayer CropScience and Daimler to cooperate in Jatropha biodiesel project
A new high-potential biofuel crop more
Expanded Labeling for MabCampath® in Europe
B-cell chronic lymphocytic leukemia (B-CLL): more